XenoPort, located Santa Clara, Calif., is a publicly held biopharmaceutical company, which develops products that harness the body's intrinsic transport systems to improve the oral absorption, distribution and pharmacokinetics of drugs. The company applies an integrated technology platform, consisting of transporter genomics, assay technology and proprietary chemistries to engineer drug molecules for active transport. It provides a wide range of drugs, such as XP13512, XP19986, XP21279, XP20925 for restless legs syndrome, post-herpetic neuralgia, spasticity, Parkinson s disease, and migraine and nausea. XenoPort collaborates with various biopharmaceutical partners to expand the applications of engineered drug transport technology into new fields, such as blood-brain barrier penetration and tumor targeting.
Partial Data by Infogroup (c) 2024. All rights reserved.